. .

Drug Development

( )
Involved OrganisationTypeFurther fields of acitivityFocusbased inManagementwas foundet inAddressEmailHomepageProfileContactNumber of employeesCertificatesBioProfileScientific Advisory Board
immatics biotechnologies GmbHBiotechDevelopment, MedicineImmune therapy, oncologyTübingenPaul G. Higham (CEO)
Dr. Carsten Reinhardt (CMO)
Dr. Harpreet Singh (CSO)
2000Paul-Ehrlich-Strasse 15
72076 Tübingen
Germany
Tel. +49 (0)7071-5651250
Fax +49 (0)7071-56512599
info@immatics.comwww.immatics.comimmatics is a biopharmaceutical company dedicated to the development of innova¬tive cancer immunotherapeutics.
immatics' proprietary technology for the identification of tumor-associated pep¬tides (TUMAPs) enables the development of novel anti-cancer vaccines for multiple cancer indications. immatics is currently developing two multi-TUMAP products in clinical phase II studies – IMA901 for the treatment of renal cell carcinoma (RCC) and IMA910 for the treatment of colorectal carcinoma (CRC). Further product candi¬dates are currently in pre-clinical de¬velopment.

With its unique proprietary XPRESIDENT™ discovery platform, immatics is constantly identifying very large numbers of naturally-presented tumor-associated peptides (TUMAPs) directly from primary tumor tissue. Since 2004 alone, the company has identified more than 50,000 TUMAP sequences and has secured the IP rights for those with high potential for use in cancer therapy.
immatics identifies TUMAPs which occur as natural ligands of HLA class I and II-receptors. These TUMAPs can activate cyto¬toxic T cells and T helper cells, key players of the cellular immune response, which have the ability to eradicate cancer cells once they are primed effectively.
TUMAPs are short peptides which are excellent drug candidates. They can be syn¬thesized and characterized by established, robust and fully scalable chemistry.		Dr. Harpreet Singh65“PROstat – regenerating micturition function in benign prostatic hyperplasia through immune therapy”
Identification, selection and validation of tumour-related peptides in stomach carcinomas aimed at defining a therapeutic vaccine based on immunogenic peptide epitopes.
Prof. Hans-Georg Rammensee
Prof. Cornelius Melief
Prof. Christoph Huber
Prof. Craig Slingluff
CureVac GmbHBiotechDevelopment, Medicine, Trade/DistributionCureVac GmbH specialises in RNA molecules synthesised by chemical and enzymatic means. CureVac also carries out its own research in the field of tumour therapy.TübingenDr. Ingmar Hörr (CEO)
Dr. Thomas Lander (CMO)
Dr. Florian von der Mülbe (COO)
Dr. Wolfgang Klein (CFO)
Dr. Jochen Probst (CSO)		2000Paul-Ehrlich-Str. 15
72076 Tübingen
Germany
Tel: +49 (0)7071- 920530
Fax: +49 (0)7071-9205311
info@curevac.comwww.curevac.comCureVac GmbH was founded as a spin-off of the University of Tübingen and has very quickly become established as one of the leading manufacturers of nucleic acids for use as active ingredients in pharmaceutical and therapeutic applications. CureVac GmbH’s portfolio primarily includes three products. 1) Modified and non-modified short (oligo-) RNA molecules are synthesised chemically in accordance with customers’ wishes. 2) The firm also offers RNActive™, an ultra-pure and stabilised form of mRNA that enables tissue and cells to be transfixed effectively. 3) In accordance with customers’ wishes, CureVac can create cDNA libraries in copyright-protected RNActive™ vectors.Dr. Ingmar Hoerr (ih@curevac.de)48CureVac has cGMP production facilities compliant with FDA and EMEA standardsNew approach to in vivo tissue generation through RNA technology, with skin tissue as an example
BioTeSys GmbHBiotechServices, Development, DiagnosticsAnalysis of the biological function of active ingredientsEsslingenDr. Jürgen Bernhardt (CEO)
Dr. Karin Engelhart (CSO)
Consuelo Gallardo (COO)
1999Schelztorstrasse 54-56
73728 Esslingen
Germany
Tel.: +49 (0)711-31057150
Fax: +49 (0)711-31057151
bts@biotesys.dewww.biotesys.deBioTeSys was founded in 1999 as a spin-off of the Institute of Biological Chemistry and Nutritional Science at the University of Hohenheim and has moved to the LSC (Life Science Centre) in Esslingen.

BioTeSys has established and expanded three areas of expertise for its commercial activities. These include: Analysis, whose techniques are deployed either independently or in concert with others; Cell and Tissue Culture, complete with its associated testing options and Services for Clinical Trials (applications, monitoring, coordination etc.).

The company’s own research focuses primarily on micronutrients and their enrichment for regenerating biological systems. BioTeSys uses nanoparticles as a new and smart means of transport for encapsulating active ingredients and addressing them so that they exert their effect directly on the target organ. This reduces the quantity of active ingredient in the body and avoids putting strain on the organism as a whole.

Commissioned by Pascoe Pharmazeutische Präparate GmbH, BioTeSys developed a kit for determining micronutrients. This kit currently enables the presence of vitamin C, the E vitamins, ß-carotene and lycopene to be detected in swabs taken from oral mucosal tissue.
Dr. Jürgen Bernhardt (j.bernhardt@biotesys.de)14Nutritargeting: highly-selective enrichment strategies for the regeneration of biological systems
biosyn Arzneimittel GmbHBiotechDevelopment, Medicine, Nutrigenomics, Diagnosticsbiosyn Arzneimittel GmbH was founded 1984 and is one of the first biotechnology companies. As a research oriented company biosyn focuses on oncology and intensiv care medicine.FellbachDr. Thomas Stiefel (Managing Director)
Ortwin Kottwitz (Managing Director)
1984Schorndorfer Strasse 32
70734 Fellbach
Germany
Tel: +49 (0)711-5753200
Fax: +49 (0)711-5753299
info@biosyn.dewww.biosyn.debiosyn Arzneimittel GmbH has specialised primarily in the fields of oncology and intensive care medicine biosyn currently offers around 30 drugs approved in 15 countries.
biosyn's develpoment strategy is based on biologic molecules and trace elements that have proven efficacy with few side effects. Hemocanin based products like IMMUCOTHEL® or VACMUNE® are used in bladder cancer or as carriers for therapeutic vaccines. Selenium compounds like Sodiumselenite (selenase®) are used in sepsis patients to reduce mortality.

In a double-blind, prospective study (SIC) study it could be demonstrated that high dose sodium selenite reduces the mortality rate for sepsis patients. The mortality rate among patients who were administered the drug was 42% as opposed to 57% for the control group. High dose selenium leads to a significant reduction (14,3%) in the mortality rate even in cases of severe sepsis such as septic shock.

biosyn Vertriebs AG in Balzers, Liechtenstein and the biosyn Corporation in Carlsbad, California, USA, are subsidiaries of biosyn. biosyn also has a scientific office in Austria.		Approx. 80biosyn’s laboratories in Fellbach are GMP-certified
npi electronic GmbHBiotechDevelopment, Medicine, Laboratory Techniques, Process EngineeringElectronic measuring instruments for the life sciences sector, drug-screening systemsTammHannelore Polder
Hans Reiner Polder (M.Sc.EE)
1989Hauptstrasse 96
71732 Tamm
Germany
Tel.: +49(0)7141-9730230
Fax: +49(0)7141-9730240
sales@npielectronic.comwww.npielectronic.comHans Reiner Polder founded npi in 1989 based on the method he developed to improve the measurement of intracellular signals. Using this newly-developed enhancement system, it was possible to improve the resolution capabilities of existing measuring systems. npi currently has a wide portfolio of products for recording bio-electrical signals. npi develops and sells numerous systems for use in fundamental medical, biological and drug research, such as voltage and patch clamp amplifiers, intra- and extracellular amplifiers, micromanipulators etc. The firm also offers products for drug screening and laboratory automation. npi electronic is a member of the Electrophysiology Innovation Partnership network. Hans Reiner Polder5
Synovo GmbHBiotechServices, Development, MedicineTesting methods for choosing drug candidatesTübingenDr. Michael Burnet (CEO)Paul-Ehrlich-Strasse 15
72076 Tübingen
Germany
Tel.: +49 (0)7071-964325
Fax +49 (0)7071-964326
contact@synovo.comwww.synovo.comSynovo GmbH is a pharmaceutical research company that offers services in the fields of synthetic chemistry, pharmacology, cell engineering and peptide modification.

The company’s focus lies in providing various testing methods and models – ideally using human cells, proteins or systems – for the selection of drug candidates with improved properties in terms of absorption, distribution, metabolism and elimination (ADME or DMPK). On behalf of customers from the pharmaceutical industry, Synovo is involved in projects investigating anti-inflammatory and immuno-suppressive drug optimisation and the improvement of existing technologies used for the development of new drugs from proteins and nucleic acids. This work is carried out in collaboration with public-sector laboratories.
Dr. Michael Burnet 20
flyion GmbHBiotechMedicine, Trade/Distribution, Laboratory TechniquesAutomated patch clamp technologyTübingenPD Dr. Albrecht Lepple-Wienhues (CEO)
Dr. Dirck Lassen (Vice President of Commercial Operations)
2001Waldhäuserstrasse 64
72076 Tübingen
Germany
Tel.: +49 (0)7071-688830
Fax: +49 (0)7071-6888399
info@flyion.comwww.flyion.comflyion GmbH was founded by Dr. Albrecht Lepple-Wienhues and Dr. Klaus Ferlinz in 2001 as a spin-off of the University of Tübingen (Institute of Physiology). The founders were supported by i.con.innovation.

In 1991, Erwin Neher and Bert Sakmann won the Nobel Prize in Medicine for their groundbreaking study of ion channels. In its conventional form, the patch clamp process that they developed is extremely labour intensive and demands a high degree of manual dexterity in order to yield reliable results. flyion has simplified this procedure with its patented Flip-the-Tip™ technology, which is ideally suited for automation.

The company offers a range of products based on this technology:
· The Flyscreen® 8500 is a patch clamp robot that performs high-quality ion channel screenings automatically. Several compounds can be tested one after the other.
· The PatchBox™ is a cost-effective plug&play workstation tool that can be combined with existing amplifiers, pullers and software. It is simple to operate and delivers a high success rate in the automatic formation of gigaseals and whole-cell configurations in a standard patch pipette.
· The ChipTip™ recording tips for the Flyscreen® 8500 consist of a glass pipette in a plastic casing. They ensure high success rates and allow extremely fast solution exchange within the pipette while keeping volumes to an absolute minimum for the study of the fastest ligand-dependent ion channels.
· The Feedback Microforge is a fully automatic micro glass pressure polishing system for the production of special glass pipette shapes in patch clamp technology.

As a solutions provider, and to complement its product range, flyion also offers the following services that help ensure the company’s products are used efficiently:
· hERG safety analysis of active substances
· Ion channel screening to help discover new active substance candidates
· Creation and characterisation of stably transfixed, inducible cell lines
· Optimisation of assays for automated ion channel screenings

Ulrike Jakl for general queries (info@flyon.com)
c-a-i-r biosciences GmbHBiotechDevelopmentResearch and development of new agents for treating inflammatory processesTübingenDr. Wolfgang Albrecht (CEO)TechnologiePark Tübingen/Reutlingen
Paul-Ehrlich-Str. 15
72076 Tübingen
Phone: +49 (0)7071–9652080
info@cair-biosciences.dewww.cair-biosciences.dec-a-i-r biosciences GmbH is a start-up company funded by the German Federal Ministry of Education and Research (BMBF) as part of the BioProfile programme. The world-renowned ratiopharm Group from Ulm is lead investor.
This new company specialises in the research and development of new low-molecular, anti-inflammatory drugs for the treatment of diseases such as rheumatoid arthritis, chronic inflammatory intestinal diseases, asthma and psoriasis. The research focuses on protein kinases, which perform a key function in the regulation of pro-inflammatory signal molecules (TNF-alpha, interleukin-1beta), and on enzymes of the arachidonic acid cascade (cyclooxygenases, 5-lipoxygenase). The company was founded on the basis of developments and patents originating from long-term research collaboration between the ratiopharm Group and Professor Stefan A. Laufer from the Institute of Pharmacy at Tübingen University. As a result of the protein kinase inhibitor project, a drug candidate has already been pre-clinically developed and tested on humans in an initial study. c-a-i-r biosciences has now set its sights on developing further drug candidates for clinical testing.
epikurion GmbH & Co. KGBiotechProduction of natural cosmeticsStuttgartDr.-Ing. Dierk-Oliver Kiehne
Prof. Dipl.-Ing. Andreas Zagos		Sigmaringer Str. 35
D-70567 Stuttgart
Tel.: 0711 /797328-12
Fax: 0711/797328-29
info@epikurion.dewww.epikurion.deepikurion® products are based on ancient formulations using natural materials from wild plants. In cooperation with renowned scientific institutions such as the Fraunhofer Institute, epikurion GmbH carries out experiments to identify the effect of wild plants. The active herbal ingredients are then isolated, leading to a combination of several active substances that have a joint mechanism of action.
The numerous ingredients contained in epikurion® products are effectively combined to offer the maximum of care. All products conform to BDIH, IAHF and Ökotest standards.